Elizabeth T. Birzin
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Elizabeth T. Birzin.
Journal of Parasitology | 1994
Susan P. Rohrer; Elizabeth T. Birzin; Clint H. Eary; James M. Schaeffer; Wesley L. Shoop
Membranes from both ivermectin-sensitive and -resistant Haemonchus contortus L3 larvae were examined for the presence of high affinity [3H]ivermectin binding sites. Both tissue preparations displayed high affinity drug binding sites (Kd = 0.13 nM). Receptor density (Bmax = 0.4 pmol/mg) was the same in both the sensitive and resistant nematodes suggesting that target site modification was not involved in the development of drug resistance in this particular strain of H. contortus. The H. contortus ivermectin binding site appeared to be similar to the well characterized Caenorhabditis elegans ivermectin binding site with respect to affinity for ivermectin and receptor density.
Bioorganic & Medicinal Chemistry Letters | 1999
Alexander Pasternak; Yanping Pan; Dominick Marino; Philip E.J. Sanderson; Ralph T. Mosley; Susan P. Rohrer; Elizabeth T. Birzin; Su-Er W. Huskey; Tom Jacks; Klaus D. Schleim; Kang Cheng; James M. Schaeffer; Arthur A. Patchett; Lihu Yang
Backbone cyclization of urea-based somatostatin agonists resulted in novel, orally bioavailable agonists. Binding assays confirmed that the resulting conformationally constrained cyclic ureas retained the potency of their acyclic counterparts. SAR studies subsequently led to highly potent analogs, selective for receptor subtype 2, and having good oral bioavailability.
Bioorganic & Medicinal Chemistry | 1996
Athanasios Tsipouras; Akinlolu A. Adefarati; Jan S. Tkacz; Easter G. Frazier; Susan P. Rohrer; Elizabeth T. Birzin; Avery Rosegay; Deborah L. Zink; Michael A. Goetz; Sheo B. Singh; James M. Schaeffer
A series of ophiobolins were isolated from a fungal extract based on their nematocidal activity. These compounds are non-competitive inhibitors of ivermectin binding to membranes prepared from the free-living nematode, Caenorhabditis elegans, with an inhibition constant of 15 microM. The ophiobolins which were most potent in the biological assays, ophiobolin C and ophiobolin M, were also the most potent compounds when evaluated in a C. elegans motility assay. These data suggest that the nematocidal activity of the ophiobolins is mediated via an interaction with the ivermectin binding site. The isolation, structure and biological activity of ophiobolins have been described.
Assay and Drug Development Technologies | 2003
Norbert T. Peekhaus; Marc Ferrer; Tina Chang; Oleg Kornienko; Jonathan Schneeweis; Todd Smith; Ira Hoffman; Lyndon J. Mitnaul; Jayne Chin; Paul Fischer; Tim A. Blizzard; Elizabeth T. Birzin; Wanda Chan; James Inglese; Berta Strulovici; Susan P. Rohrer; James M. Schaeffer
Estrogen action is mediated via two estrogen receptor (ER) subtypes, ERα and ERβ. Selective ER modulators with balanced high affinity for ERα and ERβ have been developed as therapeutics for the tre...
Insect Biochemistry and Molecular Biology | 1995
Susan P. Rohrer; Elizabeth T. Birzin; Scott D. Costa; Joseph P. Arena; Edward C. Hayes; James M. Schaeffer
High affinity avermectin binding sites have been identified and partially characterized in membranes from two insect species, Drosophila melanogaster and the locus Schistocerca americana. There is a 10-fold increase in the density of ivermectin binding sites associated with membranes isolated from Drosophila heads (a neuronally enriched tissue source) compared to the bodies (Bmax values were 3.5 and 0.22 pmol/mg, respectively) with only a small difference in the apparent dissociation constant (Kd values of 0.20 and 0.34 nM for heads and bodies, respectively). Membranes prepared from metathoracic ganglia of the locust, Schistocerca americana, were highly enriched in high affinity avermectin binding sites (Kd = 0.2 nM and Bmax = 42 pmol/mg). Using an [125I]arylazido-avermectin analog as a photoaffinity probe, a 45 kDa protein was identified in both the Drosophila head and body tissue preparations. A 45 kDa protein was also specifically labeled with [125I]azido-avermectin in the locust neuronal membranes.
Bioorganic & Medicinal Chemistry Letters | 2003
Timothy A. Blizzard; Jerry D. Morgan; Ralph T. Mosley; Elizabeth T. Birzin; Katalin Frisch; Susan P. Rohrer; Milton L. Hammond
A series of 2-phenylspiroindenes was prepared. The most active analogue (2) was found to be comparable in potency to raloxifene (1) as an estrogen receptor ligand.
Neuropharmacology | 2012
Janet Clark; S. Alves; C. Gundlah; B. Rocha; Elizabeth T. Birzin; S.-J. Cai; Rosemarie Beth Flick; Edward C. Hayes; K. Ho; Sudha Warrier; Lee-Yuh Pai; Joel B. Yudkovitz; R. Fleischer; Lawrence F. Colwell; Susan Li; Hilary A. Wilkinson; James M. Schaeffer; R. Wilkening; E. Mattingly; Milton L. Hammond; Susan P. Rohrer
Estrogen acts through two molecularly distinct receptors termed estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) which bind estradiol with similar affinities and mediate the effects of estrogen throughout the body. ERα plays a major role in reproductive physiology and behavior, and mediates classic estrogen signaling in such tissues as the uterus, mammary gland, and skeleton. ERβ, however, modulates estrogen signaling in the ovary, the immune system, prostate, gastrointestinal tract, and hypothalamus, and there is some evidence that ERβ can regulate ERα activity. Moreover, ERβ knockout studies and receptor distribution analyses in the CNS suggest that this receptor may play a role in the modulation of mood and cognition. In recent years several ERβ-specific compounds (selective estrogen receptor beta modulators; SERM-beta) have become available, and research suggests potential utility of these compounds in menopausal symptom relief, breast cancer prevention, diseases that have an inflammatory component, osteoporosis, cardiovascular disease, and inflammatory bowel disease, as well as modulation of mood, and anxiety. Here we demonstrate an antidepressant-like effect obtained using two SERM-beta compounds, SERM-beta1 and SERM-beta2. These compounds exhibit full agonist activity at ERβ in a cell based estrogen response element (ERE) transactivation assay. SERM-beta1 and 2 are non-proliferative with respect to breast as determined using the MCF-7 breast cancer cell-based assay and non-proliferative in the uterus as determined by assessing the effects of SERM-beta compounds on immature rat uterine weight and murine uterine weight. In vivo SERM-beta1 and 2 are brain penetrant and display dose dependent efficacy in the murine dorsal raphe assays for induction of tryptophan hydroxylase mRNA and progesterone receptor protein. These compounds show activity in the murine forced swim test and promote hippocampal neurogenesis acutely in rats. Taken together these data suggest that ERβ may play an important role in modulating mood and the ERβ specific compounds described herein will be useful tools for probing the utility of an ERβ agonist for treating neuroendocrine-related mood disturbance and menopausal symptoms.
Bioorganic & Medicinal Chemistry Letters | 2000
Zhixiong Ye; Ying-Duo Gao; Raman K. Bakshi; Meng-Hsin Chen; Susan P. Rohrer; Scott D. Feighner; Sheng-Shung Pong; Andrew D. Howard; Allan D. Blake; Elizabeth T. Birzin; Louis Locco; Rupa M. Parmar; Wanda W.-S. Chan; James M. Schaeffer; Roy G. Smith; Arthur A. Patchett; Ravi P. Nargund
Quinazolinone derivatives were synthesized and evaluated as non-peptidic growth hormone secretagogues. Modeling guided design of quinazolinone compound 21 led to a potency enhancement of greater than 200-fold compared to human growth hormone secretagogue affinity of a screening lead 4.
Maturitas | 2009
Evan E. Opas; Angela Scafonas; Pascale V. Nantermet; Robert R. Wilkening; Elizabeth T. Birzin; Hilary A. Wilkinson; Lawrence F. Colwell; James M. Schaeffer; Dwight A. Towler; Gideon A. Rodan; Azriel Schmidt
OBJECTIVE To test the role of ERbeta in the control of estrogen-dependent thermoregulation in rats. METHODS Test the ability of an ERbeta-selective ligand to suppress the elevation in basal rat tail skin temperature (TST) caused by ovariectomy (OVX). RESULTS ERbeta-19 is a tetrahydrofluorenone ERbeta-selective ligand that displaces 0.1 nM estradiol from ERbeta with an IC50 of 1.8 nM compared to an IC50 of 141 nM for ERalpha. Like estradiol, it acts as an agonist on ERbeta-mediated transactivation and transrepression with 25- and 60-fold selectivity, respectively, over ERalpha-controlled transcription. Administration of estradiol to estrogen-depleted rats suppresses the ovariectomy-induced elevation of TST. Similar treatment of OVX rats with ERbeta-19 also results in suppression of elevated TST. However, in contrast to estradiol, ERbeta-19 does not suppress body weight, does not increase uterine weight, nor does it stimulate uterocalin biomarker expression which is under the control of ERalpha. Thus, the ERbeta-19 suppression of rat TST is mediated by ERbeta without eliciting the activity of ERalpha. CONCLUSION Estrogen-sensitive thermoregulation in ovariectomized rats can be controlled by an ERbeta-selective ligand.
Analytical Biochemistry | 2002
Elizabeth T. Birzin; Susan P. Rohrer
Three high-throughput screening methods for quantitating 125I-SS14 binding to human somatostatin receptor 2 (hSST2) have been developed. Microplate-based separation assays were performed in Packard Unifilter and Millipore Multiscreen plates. A homogeneous ligand-binding assay was developed by employing wheat germ agglutinin (WGA)-coated Flashplates. Apparent dissociation constants for 125I-SS14 binding to hSST2 were obtained with each method. IC(50) values were determined for 12 compounds using each of the methods. Similar IC(50) values were obtained for each compound with all of the methods. The WGA-Flashplate is suitable for fully automated high-throughput screening whereas the Unifilter and Multiscreen methods are more suitable for semiautomated and manual screening applications.